Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01EY036042 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Eye Institute (NEI) | NIH |
Not provided
Not provided
Not provided
Persons who do not have glaucoma will have pictures taken of the optic nerve with a standard camera before and 2 weeks after starting to take a daily glaucoma eye drop to lower eye pressure. These data will be used to compare to the same procedure performed with glaucoma patients to study how glaucoma injures the eye.
The present proposal seeks to measure biomechanical strains in age-matched control subjects who do not have Open-angle Glaucoma (OAG), using the same non-invasive imaging methods as in the above programs. This is necessary as even undamaged OAG eyes may have different biomechanical properties at baseline than do non-OAG eyes. While there are some limited methods to test strains in control eyes, to compare normal to OAG responses robustly, the same methods of changing intra-ocular pressure (IOP) must be applied-namely to lower IOP by delivery of FDA-approved agent, latanoprost, as has been done in the investigator's OAG subjects. The method of measuring strain requires images taken at two different IOP levels.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Study group | Experimental | The participants will take an approved glaucoma eye drop, latanoprost, for less than one month, with pictures of the eyes at baseline and while taking the drop. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Latanoprost (0.005%) | Drug | Participants take the eye drop daily for less than one month |
|
| Measure | Description | Time Frame |
|---|---|---|
| Optic nerve head strain | Biomechanical strain measured by optical coherence tomography | up to 1 month |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Harry A Quigley, MD | Contact | 410 955 6051 | hquigley@jhmi.edu | |
| Farzaneh Dadvar, MD | Contact | fdadvar1@jh.edu |
| Name | Affiliation | Role |
|---|---|---|
| Harry Quigley, MD | Johns Hopkins University | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005901 | Glaucoma |
| ID | Term |
|---|---|
| D009798 | Ocular Hypertension |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077338 | Latanoprost |
| ID | Term |
|---|---|
| D011461 | Prostaglandins F, Synthetic |
| D011465 | Prostaglandins, Synthetic |
| D011453 | Prostaglandins |
| D015777 | Eicosanoids |
Not provided
Not provided
Not provided
Not provided
Not provided
Biostatistician
Not provided
| D005231 |
| Fatty Acids, Unsaturated |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D012898 | Autacoids |
| D018836 | Inflammation Mediators |
| D001685 | Biological Factors |